Abbott Laboratories $ABT Shares Sold by Mariner LLC

Key Points

• Mariner LLC reduced its Abbott Laboratories stake by 2.9% in the fourth quarter, selling 54,423 shares and leaving it with 1,838,997 shares worth about $230.4 million.
• Abbott reported stronger-than-expected quarterly results, with EPS of $1.15 topping estimates and revenue of $11.16 billion beating forecasts; the company also reiterated guidance for FY 2026.
• Analysts remain mostly positive but have trimmed price targets, with several firms lowering their targets while consensus still stands at a “Moderate Buy” and an average target price of $118.38.

Mariner LLC lessened its position in Abbott Laboratories (NYSE:ABT - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,838,997 shares of the healthcare product maker's stock after selling 54,423 shares during the quarter. Mariner LLC owned about 0.11% of Abbott Laboratories worth $230,412,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after buying an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC increased its stake in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after acquiring an additional 162 shares during the last quarter. United Bank raised its holdings in shares of Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after acquiring an additional 2,001 shares during the period. Main Street Financial Solutions LLC boosted its position in shares of Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after acquiring an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in shares of Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after purchasing an additional 292,547 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating for the company in a report on Friday, April 17th. Barclays cut their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating for the company in a report on Monday, April 20th. Piper Sandler cut their price target on shares of Abbott Laboratories from $135.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, April 17th. Benchmark cut their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating for the company in a report on Friday, April 17th. Finally, Oppenheimer cut their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating for the company in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $118.38.

Abbott Laboratories Stock Down 0.3%

Abbott Laboratories stock opened at $87.89 on Monday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a 50 day moving average price of $91.46 and a 200 day moving average price of $107.84. The company has a market capitalization of $153.08 billion, a PE ratio of 24.62, a price-to-earnings-growth ratio of 1.47 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the firm earned $1.09 EPS. The firm's revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.9%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is 70.59%.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau bought 2,200 shares of the company's stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares of the company's stock, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Daniel J. Starks purchased 10,000 shares of the company's stock in a transaction on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares of the company's stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.